Paras Biopharmaceuticals Finland Oy

Biosimilars Pipeline & Technologies

Development of Recombinant Expression Systems & Process Technologies for Biologics & Biosimilars:

Paras Biopharmaceuticals is actively engaged in research & development and is offering partnership for further development (including clinical development) on the following biosimilars:

• Recombinant Teriparatide (Forteo®Biosimilar).
• Recombinant IL1-RA / Anakinra (Kineret®Biosimilar).
• Analog Insulin Aspart.
• Recombinant Romiplostim (Nplate®Biosimilar).
• Further biologics are in the pipeline.

Due to its own technologies, Paras Biopharmaceuticals has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Biopharmaceuticals' proprietary technology platform which includes Diabrid^®, Noblecleav^®, Biomultifold^® & Cytofold StructQuant^® technologies.

Forteo^®, Kineret^® and Nplate^® are registered trademarks of/marketed by Eli Lilly, Sobi Sweden and Amgen USA respectively * Source Globa